MX2021006969A - Ligante peptidico. - Google Patents

Ligante peptidico.

Info

Publication number
MX2021006969A
MX2021006969A MX2021006969A MX2021006969A MX2021006969A MX 2021006969 A MX2021006969 A MX 2021006969A MX 2021006969 A MX2021006969 A MX 2021006969A MX 2021006969 A MX2021006969 A MX 2021006969A MX 2021006969 A MX2021006969 A MX 2021006969A
Authority
MX
Mexico
Prior art keywords
sulfonamide
conjugate
formula
peptide binder
active pharmaceutical
Prior art date
Application number
MX2021006969A
Other languages
English (en)
Inventor
Nils Rackelmann
Michael Podeschwa
Stefan Guessregen
Perez Maria Mendez
Martin Will
Thomas Boehme
Garea Ana Villar
Laurent Bialy
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021006969A publication Critical patent/MX2021006969A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una sulfonamida de fórmula (A); un conjugado que comprende una sulfonamida de fórmula (I) y un principio activo farmacéutico; un proceso para preparar un conjugado que comprende una sulfonamida de fórmula (I) y un principio activo farmacéutico; una composición farmacéutica que comprende el conjugado que comprende una sulfonamida de fórmula (I) y un principio activo farmacéutico; y el uso del conjugado como medicamento.
MX2021006969A 2018-12-11 2019-12-10 Ligante peptidico. MX2021006969A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18306659 2018-12-11
EP18306657 2018-12-11
EP18306658 2018-12-11
PCT/EP2019/084433 WO2020120479A1 (en) 2018-12-11 2019-12-10 Peptide binder

Publications (1)

Publication Number Publication Date
MX2021006969A true MX2021006969A (es) 2021-07-15

Family

ID=68806785

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021006970A MX2021006970A (es) 2018-12-11 2019-12-10 Analogos de insulina que tienen una afinidad de union disminuida al receptor de insulina.
MX2021006969A MX2021006969A (es) 2018-12-11 2019-12-10 Ligante peptidico.
MX2021006972A MX2021006972A (es) 2018-12-11 2019-12-10 Conjugados de insulina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021006970A MX2021006970A (es) 2018-12-11 2019-12-10 Analogos de insulina que tienen una afinidad de union disminuida al receptor de insulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006972A MX2021006972A (es) 2018-12-11 2019-12-10 Conjugados de insulina.

Country Status (15)

Country Link
US (2) US11098102B2 (es)
EP (3) EP3894435A1 (es)
JP (3) JP2022511567A (es)
KR (3) KR20210102345A (es)
CN (3) CN113395982A (es)
AU (3) AU2019398579A1 (es)
BR (3) BR112021011099A2 (es)
CA (3) CA3122636A1 (es)
CO (1) CO2021007453A2 (es)
IL (3) IL283803A (es)
MX (3) MX2021006970A (es)
PH (1) PH12021551339A1 (es)
SG (3) SG11202106168VA (es)
TW (3) TW202039437A (es)
WO (3) WO2020120479A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112876388B (zh) * 2021-01-14 2023-03-31 山东大学 一种gpr120激动剂及其制备方法与应用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114230451A (zh) * 2021-12-29 2022-03-25 上海药坦药物研究开发有限公司 卤代酸类化合物的制备方法
WO2023144277A1 (en) * 2022-01-26 2023-08-03 Sanofi Insulin conjugates
WO2023247640A1 (en) 2022-06-23 2023-12-28 Sanofi Single chain insulins and fc conjugates thereof
CN115947822B (zh) * 2022-07-04 2023-08-18 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9407508A (pt) 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
DE69629210T2 (de) 1995-03-17 2004-04-22 Novo Nordisk A/S Insulinabkömmlinge
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
WO1999021573A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Fatty acid-acylated insulin analogs
KR20070029247A (ko) 2004-07-08 2007-03-13 노보 노르디스크 에이/에스 폴리펩티드 연장 태그
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
ES2435522T3 (es) 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
CN102660614A (zh) 2005-08-16 2012-09-12 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
ES2387955T3 (es) 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
ES2548393T3 (es) 2006-05-09 2015-10-16 Novo Nordisk A/S Derivado de insulina
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
EP2074141B1 (en) 2006-09-22 2016-08-10 Novo Nordisk A/S Protease resistant insulin analogues
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20100216691A1 (en) 2007-07-16 2010-08-26 Novo Nordisk A/S Protease Stabilized, Pegylated Insulin Analogues
WO2009022005A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
DK2910570T3 (en) * 2008-03-18 2017-01-30 Novo Nordisk As Protease-stabilized acylated insulin analogues.
WO2009121884A1 (en) 2008-04-01 2009-10-08 Novo Nordisk A/S Insulin albumin conjugates
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
EP2352513B1 (en) 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CN102245633A (zh) 2008-12-09 2011-11-16 诺沃—诺迪斯克有限公司 新的胰岛素类似物
AU2009335712B2 (en) 2008-12-19 2015-09-17 Indiana University Research And Technology Corporation Insulin analogs
EP2376521B1 (en) 2008-12-19 2016-04-13 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
WO2010130638A1 (en) * 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
EA023925B1 (ru) * 2010-04-27 2016-07-29 Зилэнд Фарма А/С Пептидные конъюгаты агонистов рецептора glp-1 и их применение
US20130143803A1 (en) 2010-05-10 2013-06-06 Novo Nordisk A/S Process for the Preparation of Insulin-Zinc Complexes
WO2011163462A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US20140315797A1 (en) 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
US9260503B2 (en) 2011-06-15 2016-02-16 Novo Nordisk A/S Multi-substituted insulins
EP2784085A4 (en) 2011-12-15 2015-07-08 Shanghai Hengrui Pharm Co Ltd HUMAN INSULIN ANALOG AND ACYLATED DERIVATIVITY THEREOF
CN109180802A (zh) 2011-12-15 2019-01-11 爱德迪安（北京）生物技术有限公司 具有降血糖作用的化合物、组合物及其用途
CN104364262A (zh) 2011-12-21 2015-02-18 诺沃—诺迪斯克有限公司 N末端修饰的胰岛素衍生物
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
KR102163936B1 (ko) 2012-11-05 2020-10-13 케이스 웨스턴 리저브 유니버시티 장기-활성 싱글-체인 인슐린 유사체
ES2868351T3 (es) 2013-02-26 2021-10-21 Hanmi Pharm Ind Co Ltd Conjugados de análogos de insulina y usos de los mismos
CA2904332A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EP2976096B1 (en) 2013-03-20 2019-02-27 Novo Nordisk A/S Insulin dosing regimen
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
US20160115216A1 (en) 2013-06-07 2016-04-28 Novo Nordisk A/S Method for Making Mature Insulin Polypeptides
WO2015016293A1 (ja) * 2013-08-02 2015-02-05 国立大学法人 富山大学 （ベンゼンスルホニルアミノ）ベンズアミド誘導体およびそれらを有効成分とするｓｈｉｐ２阻害剤
EP3098235A4 (en) 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
WO2016001185A1 (en) 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
US20180000742A1 (en) 2015-01-29 2018-01-04 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating
WO2016172269A2 (en) 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
KR20180048607A (ko) 2015-08-25 2018-05-10 노보 노르디스크 에이/에스 세정 챔버를 가진 의료용 주사 장치
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
CN108368163A (zh) 2015-08-25 2018-08-03 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
PL239062B1 (pl) 2016-01-22 2021-11-02 Inst Biotechnologii I Antybiotykow Sposób wytwarzania insuliny i jej pochodnych
CN114478747B (zh) 2016-08-02 2024-06-14 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
EP3517544A4 (en) 2016-09-23 2020-06-03 Hanmi Pharm. Co., Ltd. INSULIN ANALOG HAVING REDUCED INSULIN RECEPTOR BINDING FORCE AND USE THEREOF
WO2018094388A1 (en) 2016-11-21 2018-05-24 Case Western Reserve University Rapid-acting insulin analogues of enhanced stability
EP3554534B1 (en) 2016-12-16 2021-06-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
CN110545849A (zh) 2017-02-03 2019-12-06 韩美药品株式会社 具有增加的持续性的生理活性物质的缀合物及其应用
MX2019011297A (es) 2017-03-23 2019-11-12 Hanmi Pharm Ind Co Ltd Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo.
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
KR20190036956A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 지속형 단쇄 인슐린 아날로그 및 이의 결합체
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery

Also Published As

Publication number Publication date
IL283801A (en) 2021-07-29
AU2019398402A1 (en) 2021-07-29
EP3893934A1 (en) 2021-10-20
BR112021011156A2 (pt) 2021-10-26
IL283803A (en) 2021-07-29
BR112021011050A2 (pt) 2021-08-31
CA3122637A1 (en) 2020-06-18
CN113396157A (zh) 2021-09-14
SG11202106168VA (en) 2021-07-29
KR20210102346A (ko) 2021-08-19
CA3122636A1 (en) 2020-06-18
MX2021006972A (es) 2021-08-16
TW202039539A (zh) 2020-11-01
WO2020120477A1 (en) 2020-06-18
SG11202106166TA (en) 2021-07-29
JP2022511567A (ja) 2022-01-31
PH12021551339A1 (en) 2021-11-29
CA3122632A1 (en) 2020-06-18
TW202039437A (zh) 2020-11-01
CO2021007453A2 (es) 2021-06-21
TW202039438A (zh) 2020-11-01
MX2021006970A (es) 2021-07-15
SG11202106167XA (en) 2021-07-29
EP3894391A1 (en) 2021-10-20
EP3894435A1 (en) 2021-10-20
IL283800A (en) 2021-07-29
WO2020120479A1 (en) 2020-06-18
KR20210102347A (ko) 2021-08-19
US20220048968A1 (en) 2022-02-17
CN113423691A (zh) 2021-09-21
WO2020120463A1 (en) 2020-06-18
US20200181223A1 (en) 2020-06-11
BR112021011099A2 (pt) 2021-10-26
US11098102B2 (en) 2021-08-24
AU2019398658A1 (en) 2021-07-29
KR20210102345A (ko) 2021-08-19
JP2022513776A (ja) 2022-02-09
AU2019398579A1 (en) 2021-07-29
JP2022513775A (ja) 2022-02-09
CN113395982A (zh) 2021-09-14

Similar Documents

Publication Publication Date Title
MX2021006969A (es) Ligante peptidico.
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12017500281B1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
MX2021009285A (es) Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
PH12020550683A1 (en) Novel bradykinin b2 receptor antagonists
EA201391018A1 (ru) Препараты иммуносупрессантов
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
CR20210216A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
MX2022006519A (es) Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo.
EA201692298A1 (ru) Производные карбоксамидов
ZA202103090B (en) Pharmaceutical formulations of cyclosporine analogs
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
MX2022002185A (es) Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso.
MX2022006502A (es) Composiciones farmaceuticas.